The company now expects to file for full approval by year’s end and has a variant-specific shot in advanced testing. But the long-term prospects for AstraZeneca’s new vaccine business are unclear.
The company now expects to file for full approval by year’s end and has a variant-specific shot in advanced testing. But the long-term prospects for AstraZeneca’s new vaccine business are unclear.
Copyright © 2024 | WordPress Theme by MH Themes
